Document is current
Any future updates will be listed below
-
Authors
Jamy, Omer https://orcid.org/0000-0003-2411-4742
Diebold, Kendall
Davis, Kenneth
Bachiashvili, Kimo
Rangaraju, Sravanti
Vachhani, Pankit
Godby, Kelly N.
Salzman, Donna
Bhatia, Ravi https://orcid.org/0000-0001-5740-2316
- License Information
-
More Information
Article History
Received: 13 March 2023
Revised: 23 March 2023
Accepted: 24 March 2023
First Online: 3 April 2023
Competing interests
: PV has received consulting fees from AbbVie, Amgen, Blueprint Medicines, CTI biopharma, Genentech, Incyte, Novartis, and Pfizer. All other authors have no relevant conflict of interest to disclose.
